Marek Jutel

TL;DR: A deviation towards a regulatory/suppressor T cell response during SIT and in normal immunity as a key event for the healthy immune response to mucosal antigens is demonstrated.

TL;DR: These guidelines aim to provide evidence‐based recommendations for the recognition, risk factor assessment, and the management of patients who are at risk of, are experiencing, or have experienced anaphylaxis, and to prevent future episodes by developing personalized risk reduction strategies including, where possible, commencing allergen immunotherapy.

TL;DR: It is reported that histamine enhances TH1-type responses by triggering the histamine receptor type 1 (H1R), whereas bothTH1- and TH2- type responses are negatively regulated by H2R through the activation of different biochemical intracellular signals.

TL;DR: It is concluded that ultra-rush VIT changes allergen-specific T cell reactivity and resulted in decreased IL-4 and IL-5 and increased IFN-gamma secretion in bee venom immunotherapy patients.

TL;DR: The discovery of reciprocal regulation of T cell activity by H1 and H2 receptor activation indicating histamine‐cytokine cross‐talk, as well as the characterization of the fourth histamine receptor (HR4) and its expression on numerous immune and inflammatory cells have prompted a re‐evaluation of the actions of histamine.